Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2022 - 2024)

Historic Shares Outstanding for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q1 2024 value amounting to $71.0 million.

  • Zentalis Pharmaceuticals' Shares Outstanding rose 1946.6% to $71.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $71.0 million, marking a year-over-year increase of 1946.6%. This contributed to the annual value of $70.8 million for FY2023, which is 1937.75% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Shares Outstanding stood at $71.0 million for Q1 2024, which was up 1946.6% from $70.8 million recorded in Q4 2023.
  • Over the past 5 years, Zentalis Pharmaceuticals' Shares Outstanding peaked at $71.0 million during Q1 2024, and registered a low of $45.6 million during Q1 2022.
  • Over the past 3 years, Zentalis Pharmaceuticals' median Shares Outstanding value was $59.4 million (recorded in 2023), while the average stood at $62.4 million.
  • Over the last 5 years, Zentalis Pharmaceuticals' Shares Outstanding had its largest YoY gain of 3040.1% in 2023, and its largest YoY loss of 1937.75% in 2023.
  • Over the past 3 years, Zentalis Pharmaceuticals' Shares Outstanding (Quarter) stood at $59.3 million in 2022, then grew by 19.38% to $70.8 million in 2023, then grew by 0.35% to $71.0 million in 2024.
  • Its last three reported values are $71.0 million in Q1 2024, $70.8 million for Q4 2023, and $70.6 million during Q3 2023.